menu
    • menu
    [{"orgOrder":0,"company":"Intrance Medical System","sponsor":"Erik Selin","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intrance Medical Systems Completes $17 Million Series A Financing and Appoints Ed Schutter to Board of Directors","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Intrance Medical System","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Intrance Medical System \/ Erik Selin","highestDevelopmentStatusID":"5","companyTruncated":"Intrance Medical System \/ Erik Selin"}]

    Find Clinical Drug Pipeline Developments & Deals by Intrance Medical System

    Menu

    Intrance Medical System

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Intrance Medical System

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Intrance Medical System

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbidopa,Etilevodopa,Entacapone

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Erik Selin

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Intrance Medical Systems Completes $17 Million Series A Financing and Appoints Ed Schutter to Board of Directo...

                            Details : Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, Lecigon® (in the Nordic countries and European markets) for enteral infusion (light weight infusion pump) in advanced Parkinsonâ€...

                            Brand Name : Lecigon

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2022

                            Lead Product(s) : Carbidopa,Etilevodopa,Entacapone

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Erik Selin

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth